OpenNashPodcasts

Topic

ARCH Venture Partners

7 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

Undated

ARCH Venture Partners' Fund 11 is described by host Luke Timmerman as a $1.85 billion fund for investing in new biotech startups.

“Now for this conversation, I focus mainly on what Bob and the Arch investing team want to do with the latest fund, Fund 11. It's a $1.85 billion colossus to invest in new biotech startups.”

Luke Timmerman · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:01:10

Undated

Luke Timmerman says the Fund 11 press release lists infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic and biological tools, and data sciences among its areas.

“Infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging, genomic, biological tools, data sciences.”

Luke Timmerman · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:13:07

Undated

Bob Nelsen contrasts Flagship Pioneering's incubation of companies within Flagship with ARCH's model of incubating companies within existing portfolio companies.

“While Flagship might incubate companies, a bunch of companies within Flagship, we have a model that's kind of incubating companies within companies.”

Bob Nelsen · Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing, 0:10:41

Episodes